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Abstract
We have cloned a human counterpart to a guinea pig STE20-like kinase cDNA, designated human SLK (hSLK), from a
human lung carcinomatous cell line A549 cDNA library. hSLK cDNA encodes a novel 1204 amino acid serine/threonine
kinase for which the kinase domain located at the N-terminus shares considerable homology to that of the STE20-like kinase
family. The C-terminal domain of hSLK includes both the coiled-coil structure and four Pro/Glu/Ser/Thr-rich (PEST)
sequences, but not the GTPase-binding domain (GBD) that is characteristic of the p21-activated kinase (PAK) family,
polyproline consensus binding sites, or the Leu-rich domain seen in the group I germinal center kinases (GCKs). Northern
blot analysis indicated that hSLK was ubiquitously expressed. hSLK overexpressed in COS-7 cells phosphorylates itself as
well as myelin basic protein used as a substrate. On the other hand, hSLK cannot activate any of the three well-characterized
mitogen-activated protein kinase MAPK (ERK, JNK/SAPK and p38) pathways. Moreover, hSLK kinase activity is not
upregulated by constitutive active forms of GTPases (RasV12, RacV12 and Cdc42V12). These structural and functional
properties indicate that hSLK should be considered to be a new member of group II GCKs. ß 2000 Elsevier Science B.V.
All rights reserved.
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1. Introduction
Mitogen-activated protein kinase (MAPK) cas-
cades play a critical role in transducing information
from various extracellular stimuli including growth
factors and environmental stresses to the nucleus
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domain; PAK, p21-activated kinase; MBP, myelin basic protein; MAPK, mitogen-activated protein kinase; ERK, extracellular signal-
regulated kinase; JNK, c-Jun N-terminal kinase; SAPK, stress-activated protein kinase; Cdc, cell division cycle; PH, pleckstrin-homol-
ogy; GCKR, GCK-related; GLK, GCK-like kinase; HPK1, hematopoietic progenitor kinase-1; KHS, kinase homologous to SPS1/
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[1,2]. The MAPK cascades are composed of a speci¢c
subset of MAPKK kinases (MAPKKKs), MAPK
kinases (MAPKKs) and MAPKs. A MAPKKK
phosphorylates conserved threonine and serine resi-
dues in a MAPKK, inducing the activation of a
MAPKK. An activated MAPKK leads to the activa-
tion of a MAPK through the phosphorylation of its
conserved threonine and tyrosine residues. In mam-
mals, there are three well-characterized MAPK cas-
cades, extracellular signal-regulated kinase (ERK)
[3], c-jun N-terminal kinase/stress-activated protein
kinase (JNK/SAPK) [4^6], and p38 (also known as
cytokine-suppressive anti-in£ammatory drug-binding
protein, CSBP or reactivating kinase, RK) cascades
[7,8]. The ERK cascade, a classical MAPK cascade,
is activated by growth factors and tumor-promoting
phorbol esters. By contrast, JNK/SAPK and p38 cas-
cades are strongly activated in response to stressful
stimuli such as heat and osmotic shock, UV light,
and inhibitors of protein synthesis, but not by
growth factors and phorbol esters. These kinase sub-
sets of MAPK cascades are highly conserved from
yeast to mammals.
In budding yeast Saccharomyces cerevisiae, ¢ve
MAPK cascades have been identi¢ed. One of these
cascades regulates spore formation [9,10]. The other
four cascades operate in active cells [11]: two cas-
cades operate in response to solute concentration
(Hog and MPK pathways respond to high and low
osmolarities, respectively); the remaining two cas-
cades function in relation to mating (Fus3 pathway)
and ¢lamentation (Kss1 pathway). The Fus3 path-
way is activated by the binding of peptide phero-
mone to cell-surface receptors in haploid a or K cells.
This binding activates a trimeric G protein and in
turn activates STE20 (MAPKKKK), STE11
(MAPKKK), STE7 (MAPKK) and Fus3 (MAPK).
In the Kss1 pathway, the initiation signal is not
identi¢ed; however, the same set of MAPKKKK
(STE20)-MAPKKK (STE11)-MAPKK (STE7)-
MAPK (Kss1) pathway is required to transmit sig-
nals for ¢lamentation. Thus, STE20 functions as an
important initiation kinase in MAPK pathways of S.
cerevisiae.
Recently, much attention has been directed to
MAPKKKKs in mammals since many novel serine/
threonine kinases related to STE20 (STE20-like ki-
nases (SLKs)) have been identi¢ed. SLKs are divided
as follows into three families based on their struc-
ture: p21-activated kinase (PAKs), pleckstrin-homol-
ogy domain-containing PAKs (PH-PAKs) and ger-
minal center kinase (GCKs) families [12]. PAKs and
PH-PAKs have a common feature to their C-termi-
nal (CT) catalytic and N-terminal regulatory do-
mains. The CT regulatory domain includes
GTPase-binding domain (GBD) [13], also known as
cell division cycle (Cdc) 42/Rac-interactive binding
domain (CRIB) [14], that is necessary for direct in-
teraction with Cdc42 or Rac. The interaction induces
the activation of PAK family kinases, leading to the
activation of JNK/SAPK and p38 [15^17]. At
present, four isoforms of PAKs have been identi¢ed
in the mammalian PAK family. PH-PAKs possess
the PH domain N-terminal to the GBD. No PH-
PAKs have yet been found in higher eukaryotes,
although PAK-like fragments that might encode
pieces of a mammalian PH-PAK seem to be regis-
tered in EST data bases [12].
The GCK family includes GCK [18], GCK-related
(GCKR) [19], GCK-like kinase (GLK) [20], hemato-
poietic progenitor kinase-1 (HPK1) [21,22], kinase
homologous to SPS1/STE20 (KHS) [23], mammalian
sterile 20-like (MST) 1^3 [24^26], STE20-like oxidant
stress-activated kinase-1 (SOK1) [27], Nck-interact-
ing kinase (NIK) [28] and lymphocyte-oriented ki-
nase (LOK) [29]. All members of this family share
a similar structure including an N-terminal kinase
domain and a CT long regulatory domain, but the
lack of a recognizable GBD motif. The GCK family
can be further divided into two subfamilies based on
their structural and functional properties [30]. Group
I GCKs, GCK, GCKR, GLK, HPK1, NIK and
KHS, interact with MAPK/ERK kinase kinase
(MEKK) 1, a MAPKKK; consequently they activate
the JNK/SAPK pathway, but not ERK or p38 path-
ways. Structurally, the kinases of this group contain
at least two Pro/Glu/Ser/Thr-rich (PEST) sequences
and at least two proline-rich consensus binding sites
for the Src-homology (SH)-3 domain. In addition,
their CT regulatory regions possess a leucine-rich
domain and a 140^150 amino acid stretch, the CT
region.
Group II GCKs include MST1^3, SOK1 and
LOK. These kinases have no ability to activate
ERK, JNK/SAPK or p38 pathways except for
MST1, which has been reported to activate JNK/
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SAPK and p38 MAPK pathways [31]. Although
group II GCKs share a catalytic domain homology
with group I GCKs, no conserved motifs on the CT
domains of the group II kinases have been found.
We have previously carried out PCR-based cDNA
cloning of protein kinases expressing in eosinophils,
and cloned a novel putative kinase cDNA fragment.
Full-length cDNA of this protein kinase was cloned
from a guinea pig liver cDNA library using the
cDNA fragment as a probe. The encoded polypep-
tide contains a conserved serine/threonine kinase do-
main on its N-terminus, and the kinase domain is
similar to that of STE20 [32]. In this study, we
cloned human SLK (hSLK) cDNA and characterized
the kinase. Structurally, hSLK contained a conserved
serine/threonine kinase domain on its N-terminus as
well as a CT long regulatory domain that is charac-
teristic of GCKs. Functionally, hSLK could not ac-
tivate ERK, JNK/SAPK or p38 MAPK pathways.
Furthermore, hSLK was not activated by small
GTPases Ras, Rac or Cdc42. Considering these
properties, we concluded that hSLK is a new mem-
ber of group II GCKs.
2. Materials and methods
2.1. Cell lines
The cell lines U937 (human histiocytic lymphoma),
A549 (human lung carcinoma), HepG2 (human
hepatocellular carcinoma) and COS-7 cells were ob-
tained from Human Science Research Resources
Bank (Osaka, Japan), and EoL1 (human eosinophilic
leukemia) from Riken Cell Bank (Saitama, Japan).
2.2. Molecular cloning of hSLK cDNA
Total RNA was prepared from A549 cells by the
guanidinium/cesium chloride method, and the poly-
(A)-rich RNA was puri¢ed by chromatography on
oligo (dT)-cellulose (New England Biolabs, Beverly,
MA, USA) [33,34]. cDNA synthesis was carried out
by the method of Aru¡o and Seed [35]. Brie£y,
cDNAs were synthesized using random primers
(Pharmacia, Uppsala, Sweden), and a BstXI adopter
(Takara Shuzo, Otsu, Japan) was ligated. The syn-
thesized cDNAs were fractionated by potassium ace-
tate gradient (5^20%) centrifugation. The fractions in
which the length of the cDNAs was over 3 kbp were
pooled and ligated into a BstXI-cleaved CDM8 vec-
tor (Invitrigen, Groningen, Netherlands). The ligated
plasmid DNAs were introduced into Escherichia coli
MC1061P3 cells, plated and transferred to a nitro-
cellulose membrane. The colony hybridization assay
was performed in a solution containing 50 mM Tris^
HCl (pH 8.0), 1 M NaCl, 10 mM EDTA, 0.1% so-
dium dodecyl sulfate (SDS), 1UDenhart’s solution,
and 100 Wg/ml salmon sperm DNA for 16 h at 60‡C.
The membrane was washed with a solution contain-
ing 450 mM NaCl, 45 mM sodium citrate, and 0.1%
SDS for 30 min at 60‡C. By screening approximately
4.7U105 colonies using the guinea pig SLK cDNA
fragment as a probe, two positive clones (CDM8-51
and CDM2-40) were isolated. The inserted cDNAs
were subcloned into pBluescript vector (Stratagene,
La Jolla, CA, USA) and sequenced. Gap nucleotides
between the two clones (nucleotides 3712^3733) were
ampli¢ed by reverse transcription-polymerase chain
reaction (RT-PCR) using A549 cDNA library as a
template. One set of oligonucleotide primers corre-
sponding to the 3P sequence of clone CDM8-51 (5P-
ATGCCACTTGTTGGTTGAGC-3P) and the 5P se-
quence of clone CDM2-40 (5P-ATGATCCGGTG-
GAATGCAAG-3P) were used for the RT-PCR.
The ampli¢ed cDNA was ligated into pT7Blue(R)
T vector (Novagen, Madison, WI, USA) and se-
quenced.
2.3. Northern blot analysis
RNA tissue blots were purchased from Clontech
(Palo Alto, CA, USA). Each blot contained 2 Wg of
poly(A) RNA isolated from di¡erent human tis-
sues. Prehybridization was carried out at 42‡C for
6 h in hybridization bu¡er containing 750 mM
NaCl, 50 mM NaH2PO4, 5 mM EDTA, 10UDen-
hart’s solution, 2% SDS and 100 Wg/ml denatured
salmon sperm DNA. The hSLK cDNA fragment to
be used for a probe (nucleotides 2874^3585) was la-
beled with [K-32P]dCTP (ICN Biomedicals, Costa
Mesa, CA, USA) by random priming. The blot was
hybridized with the labeled probe at 42‡C for 12 h in
hybridization bu¡er, washed once in washing bu¡er
containing 300 mM NaCl, 30 mM sodium citrate,
0.05% SDS, and washed again in another washing
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bu¡er containing 150 mM NaCl, 15 mM sodium cit-
rate and 0.1% SDS for 1 h at 50‡C. The blot was
exposed on an X-ray ¢lm for 4 days at 380‡C
2.4. Plasmids
The hemagglutinin antigen (HA) epitope-tagged
hSLK expression vector (pEF HA-hSLK) was con-
structed by adding a sequence that encodes two cop-
ies of 10 amino acid HA epitope (MYPYDVPDYA)
[36] to the N-terminus of hSLK and ligating the
cDNA into pEF [37]. The kinase-negative mutant
of hSLK (hSLK K63R), in which the Lys-63 re-
quired for ATP-binding is replaced with Arg, was
constructed by the oligonucleotide-directed mutagen-
esis method [38]. To construct the expression vectors
for HA-hSLKv592^971, HA-tagged full-length
hSLK cDNA was digested with NcoI/XhoI. A 5P
NcoI fragment and an XhoI 3P fragment were ligated
using suitable oligonucleotides (5P-CATGGTGGG-
TGC-3P and 5P-TCGAGCACCCAC-3P), and sub-
cloned into pEF. To construct the expression vectors
for HA-hSLKv976^1204 and v582^1204 mutants,
HA-tagged full-length hSLK cDNA was digested
with NcoI or XhoI, respectively, and then 5P frag-
ments were subcloned into pEF. The expression vec-
tors for HA-tagged MAPKs (pSRK3 HA-ERK2,
pSRK3 HA-JNK1 and pSRK3 HA-p38) and for con-
stitutive active forms of GTPases (pSRK3 RasV12,
pSRK3 RacV12 and pCMV5 Cdc42V12) were do-
nated by Dr. Michael Karin (University of Califor-
nia, San Diego, CA, USA) [39,40].
2.5. In vitro kinase assay
In the assay for hSLK kinase activity, the expres-
sion vectors for either HA-hSLK WT, HA-hSLK
K63R, HA-hSLKv591^972, HA-hSLKv975^1204
or HA-hSLKv591^1204 were transfected into COS-
7 cells by the DEAE-dextran method [34]. After 48 h,
the cells were lysed in lysis bu¡er containing 20 mM
Tris^HCl (pH 8.0), 0.5% Nonidet P-40, 250 mM
NaCl, 3 mM EDTA, 3 mM EGTA, 2 mM DTT,
0.5 mM phenylmethylsulfonyl£uoride (PMSF),
20 mM L-glycerophosphate, 1 mM sodium orthova-
nadate and 1 Wg/ml leupeptin. The cell lysates were
precleared with protein A-Sepharose 4B (Pharmacia)
for 1 h and incubated with anti-HA monoclonal anti-
body (mAb) (12CA5, Boehringer Mannheim, Indian-
apolis, IN, USA) for 2 h at 4‡C. The immune com-
plexes were precipitated with protein A-Sepharose
4B, washed three times with lysis bu¡er, and then
washed three times with kinase bu¡er containing
20 mM HEPES pH 7.5, 20 mM L-glycerophosphate,
10 mM p-nitrophenylphosphate, 10 mM MgCl2,
1 mM DTT and 50 WM sodium orthovanadate.
The immunoprecipitates were incubated with 20 WM
ATP, 20 WCi [Q-32P]ATP (ICN Biomedicals, Costa
Mesa, CA, USA) and 5 Wg of myelin basic protein
(MBP) in the kinase bu¡er for 30 min at 30‡C. The
kinase reaction was terminated by adding an equal
volume of 2Usample bu¡er containing 125 mM
Tris^HCl (pH 6.8), 4% SDS, 1.44 M 2-mercaptoeth-
anol, 20% glycerol and 200 Wg/ml of bromophenol
blue. The reaction products were separated by SDS^
polyacrylamide gel electrophoresis (PAGE). After
drying, the gel was subjected to autoradiography.
2.6. Western blot
To examine the MAPK activation in response to
the overexpression of hSLK, COS-7 cells were co-
transfected with pEF HA-hSLK and pSRK HA-
MAPKs (ERK, JNK or p38). The cell lysates were
separated by SDS^PAGE and electroblotted onto a
nitrocellulose membrane (Schleicher and Schuell,
Keene, NH, USA). The membrane was blocked
with 3% bovine serum albumin in TBS/T (Tris-bu¡-
ered saline with Tween 20; 50 mM Tris pH 7.4,
150 mM NaCl and 0.1% Tween 20) for 30 min at
room temperature and washed twice with TBS/T.
The membrane was incubated with either anti-active
MAPK polyclonal antibody (pAb), anti-active JNK
pAb or anti-active p38 pAb (Promega, Madison, WI,
USA) for 1 h at room temperature and then washed
three times with TBS/T. The secondary antibody,
anti-rabbit Ig conjugated to horseradish peroxidase
(Santa Cruz Biotechnology, Santa Cruz, CA, USA)
was diluted 1:10 000 and incubated with the mem-
brane for 1 h at room temperature. The membrane
was washed three times with TBS/T, and the signal
was detected by an enhanced chemiluminescence
method according to the manufacturer’s instructions
(Wako, Osaka, Japan).
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3. Results
3.1. Cloning and sequencing of the hSLK
Before the construction of the cDNA library, we
assessed the expression levels of hSLK mRNA in
EoL1, U937, A549 and HepG2 cell lines by North-
ern blot analysis using a guinea pig SLK cDNA as a
probe. Since hSLK mRNA was abundantly ex-
pressed in a human lung carcinomatous cell line
A549 (data not shown), we prepared and screened
the A549 cDNA library using the guinea pig SLK
cDNA fragment as a probe. Two positive clones
(3.7 kbp and 2.1 kbp) were identi¢ed. A homology
Fig. 2. Alignment of the catalytic domain of hSLK with that of other STE20 family members. The predicted amino acid sequence of
the kinase domain of hSLK was aligned with the corresponding domains of hLOK, hMST1, hSOK1, hGCK, hHPK1, hKHS, mNIK,
hPAK1 and STE20. The 11 subdomains conserved in protein kinases [41] are indicated in Roman numbers above the sequences. The
numbers at the right indicate the amino acid positions. The identical sequences among at least ¢ve proteins are highlighted with solid
boxes.
Fig. 1. Nucleotide and predicted amino acid sequences of hSLK. A: The conserved serine/threonine kinase domain is boxed, and the
ATP-binding site is circled. Potential PEST sequences are double-underlined, and the region of the coiled-coil structure is shaded. The
stop codon (TGA) 171 bp 5P of the putative initiation codon is underlined, and the polyadenylation signal in the 3P untranslated re-
gion is dotted. Numbering of the nucleotide and amino acid positions is indicated on the left. B: The schematic diagram illustrating
the domain structure of hSLK. The serine/threonine kinase domain is drawn as a hatched box. Potential PEST sequences are drawn
as solid boxes, and the region of the coiled-coil structure is drawn as a shaded box.
6
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search against guinea pig SLK showed that the 3.7
kbp and 2.1 kbp fragments included initiation and
termination codons, respectively. Since these two
fragments did not overlap each other, we determined
the gap nucleotide sequence between these two clones
(nucleotides 3713^3734) by the RT-PCR method. As
shown in Fig. 1, the complete nucleotide sequence of
hSLK cDNA predicted an open reading frame of
1204 amino acids with a calculated molecular mass
of 138 993 Da. The deduced amino acid sequence
contained the conserved serine/threonine kinase do-
main [41] on its N-terminus. In the kinase domain,
hSLK displays a similarity to other SLKs with about
40% identity (46.1% identical to hGCK, 41.0% to
hHPK1, 45.3% to hKHS, 45.1% to hMST1, 44.3%
to hSOK1, 41.9% to hPAK1, 42.9% to mNIK and
39.4% to yeast STE20) (Fig. 2). hSLK is most similar
to hLOK, which belongs to the SLK family, and the
kinase domain of hSLK is 77.2% identical to that of
hLOK. Furthermore, it is notable that the CT do-
main of hSLK is 43.9% identical to that of hLOK.
Since the CT domain of hLOK includes the coiled-
coil structure, we attempted to determine whether
hSLK also contains the structure using ‘COILS’, a
program that predicts for the coiled-coil region [42].
This examination showed that hSLK possesses the
region of the coiled-coil structure on its C-terminus
(amino acids 827^1168) (Fig. 1A,B). Since some
members of the GCK family have the PEST se-
quence, we con¢rmed the existence of the sequence
using a program called PEST¢nd [43,44]. Interest-
ingly, hSLK was found to have four PEST sequences
between its kinase domain and the region of the
coiled-coil structure.
3.2. Tissue distribution of hSLK mRNA
Northern blot analysis of human tissue mRNA
using the CT regulatory domain of hSLK (nucleo-
tides 2874^3585) as a probe indicated the existence of
three distinct transcripts (8.5, 7.0 and 5.0 kbp) and
the most abundant expression of one 7.0 kbp tran-
script in all tissues. The highest levels of expression
for these transcripts were detected in the heart and
the skeletal muscle, with intermediate levels being
detected in the placenta, pancreas, prostate, testis,
uterus and small intestine (Fig. 3).
3.3. Kinase activity of hSLK
To investigate the kinase activity of hSLK, we
constructed ¢ve expression vectors for HA epitope-
tagged wild-type and mutated hSLKs, as shown in
Fig. 4A. hSLK K63R, a kinase-dead mutant, was
constructed by changing the 63rd lysine of the
ATP-binding site to arginine. hSLK can be divided
into three regions based on the similarities to guinea
pig SLK: an N-terminal highly homologous region
including the kinase domain (amino acids 1^548,
84.5% identical to guinea pig SLK), a CT highly
homologous region (amino acids 733^1204, 91.7%)
and an intermediate region with relatively low ho-
mology (amino acids 549^732, 43.7% identical). We
hypothesized that the CT highly homologous region
Fig. 3. Norther blot analysis of hSLK mRNA. Northern blots (2.2 M formaldehyde-1.2% agarose; Clontech) containing poly(A)
RNA (2 Wg) from a variety of human tissues were probed with the hSLK cDNA fragment (nucleotides 2874^3585) (upper panels).
The same blots were probed with L-actin cDNA to check the integrity of the RNA (lower panels).
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may play an important role in regulating the kinase
activity of hSLK. To investigate which part of this
region would regulate this kinase activity, we con-
structed expression vectors for three distinct hSLK
deletion mutants (v592^971, v976^1204 and v592^
1204; Fig. 4A) by dividing the CT highly homolo-
gous region into two parts at an XhoI site. To con-
¢rm the expression of hSLK mutants, COS-7 cells
were transfected with each expression vector. Cell
lysates were separated on SDS^PAGE and immuno-
blotted with anti-HA mAb (12CA5). As shown in
Fig. 4B, clear single bands derived from transfected
cDNA were detected in each lane. In the transfec-
tants of full-length hSLK cDNA (hSLK WT and
K63R), the expressed proteins were detected at ap-
proximately 200 kDa. Since the calculated molecular
mass of hSLK protein is approximately 140 kDa, the
di¡erence in molecular mass might be due to post-
translational modi¢cation.
The expressed HA-tagged hSLK proteins were im-
munoprecipitated with anti-HA mAb, and an in vitro
kinase assay was then performed by incubating these
immunocomplexes using MBP as a substrate. hSLK
WT markedly phosphorylated MBP, but hSLK
K63R did not. Moreover, an approximately 200
kDa phosphorylated band was detected in hSLK
WT immunoprecipitates. These results indicate that
hSLK had not only the kinase activity for the sub-
strate but also autophosphorylation activity. Com-
pared with hSLK WT, no remarkable changes in
kinase activity for MBP and autophosphorylation
levels were observed in the three deletion mutants
(Fig. 4C).
3.4. Overexpression of hSLK could not activate
MAPKs
In mammals, three MAPK cascades have been
well-characterized. One is the ERK pathway, a clas-
sical MAPK cascade, that responds to growth fac-
Fig. 4. Kinase activity of hSLK expressed in COS-7 cells. A: a
schematic diagram of hSLK and its mutants. Deletions in the
C-terminus of hSLK were performed by using unique restriction
enzyme sites as described in Section 2. hSLK K63R is a kinase
inactive mutant, in which the critical lysine (amino acid 63) re-
quired for ATP-binding has been changed to an arginine. The
kinase domains are drawn as hatched boxes. COS-7 cells were
transfected with pEF HA (vector), wild-type HA-tagged hSLK
(WT) or hSLK mutants ligated into a pEF HA vector (K63R,
v592^971, v976^1204 and v582^1204). B: Cell lysates were sub-
jected to SDS^PAGE and immunoblotted with anti-HA mAb.
C: After immunoprecipitaitons, an in vitro kinase assay was
performed using [Q-32p]ATP and MBP as a substrate. The reac-
tion products were separated by SDS^PAGE and subjected to
autoradiography.
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tors. The other two MAPKs, JNK/SAPK and p38,
are activated by stressful stimuli such as anisomycin
and NaCl. Many of the SLKs such as PAKs, GCK,
HPK1, NIK, KHS and MST1 have been shown to
activate JNK/SAPK and/or p38 MAPK cascades.
We attempted to determine which of the three
MAPKs would be activated by hSLK. HA-tagged
hSLK or its mutants were co-transfected to COS-7
cells with HA-tagged ERK, JNK/SAPK or p38. The
activation of these MAPKs was analyzed by immu-
noblot with anti-active ERK (Fig. 5A), anti-active
JNK/SAPK (Fig. 5B) or anti-active p38 (Fig. 5C)
antibodies. hSLK WT and its deletion mutants
were not able to activate any of these MAPKs. In
contrast, when COS-7 cells transfected with ERK,
JNK/SAPK or p38 were stimulated with 100 ng/ml
EGF, 10 Wg/ml anisomycin or 0.7 M NaCl, respec-
tively, these MAPKs were su⁄ciently activated. In
these experiments, the expression levels of each of
the hSLK mutants (data not shown) and MAPKs
(bottom lane of each panel) were almost the same
as those checked with anti-HA mAb. These results
indicate that hSLK cannot activate ERK, JNK/
SAPK or p38 MAPK pathways.
3.5. Active forms of Ras, Rac1 and Cdc42 are not the
up-stream regulators of hSLK
In yeast, STE20 is activated by an active form of
Cdc42p. Similarly, PAK family kinases (PAKs 1^3)
Fig. 5. No activation of ERK, JNK, p38 by hSLK. COS-7 cells were transfected with wild-type hSLK (WT) or its mutants as de-
scribed in Fig. 4A in the presence of pSRK HA-ERK (A), pSRK HA-JNK (B) and pSRK HA-p38 (C). The cell lysates were separated
by SDS^PAGE and immunoblotted with anti-active MAPK, anti-active JNK or anti-active p38 pAbs (upper panel). The expression
levels of ERK were checked by reprobing the same blot with anti-HA mAb (lower panel). As a positive control, the cell lysates of
pSRK HA-ERK-, pSRK HA-JNK- and pSRK HA-p38-transfected COS-7 cells stimulated with EGF (A), anisomycin (B) and NaCl
(C), respectively, were immunoblotted with anti-active MAPK antibodies.
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have been reported to interact with and be activated
by active forms of Rac1 and Cdc42 [45^47]. There-
fore, we examined whether Ras, Rac1 or Cdc42
could increase the kinase activity of hSLK. Expres-
sion vectors for constitutive active forms of small G
proteins (RasV12, Rac1V12 or Cdc42V12) were co-
transfected with HA-tagged hSLK into COS-7 cells.
Total cell lysates were immunoprecipitated with anti-
HA mAb, and the immunoprecipitates were sub-
jected to an in vitro kinase assay. No changes in
the phosphorylation levels of hSLK and MBP were
observed, even though constitutive active forms of
GTPases were co-transfected (Fig. 6A,B). In hSLK
K63R transfectants, phosphorylated bands were
not detected at all. In order to con¢rm the GTPase
activity of the small G proteins, RasV12 or
Rac1V12/Cdc42V12 were co-transfected with HA-
tagged ERK or JNK, respectively, and the cell ly-
sates were immunoblotted with anti-active ERK or
anti-active JNK antibodies. As shown in Fig. 6C,
RasV12 and Rac1V12/Cdc42V12 activated ERK
and JNK pathways, respectively [48,49]. These re-
sults indicate that Ras, Rac1 and Cdc42 are not reg-
ulators of hSLK.
4. Discussion
In this study, we were able to clone a novel human
serine/threonine protein kinase, hSLK. Because the
kinase domain of hSLK located on its N-terminus
is similar to that of STE20 (a MAPKKKK of
Fig. 6. No activation of hSLK by constitutive active forms of GTPases. A and B: Constitutive active forms of GTPases (RasV12,
Rac1V12 or Cdc42V12) were co-transfected with HA-tagged hSLK WT (WT) or the hSLK K63R (K63R) described in Fig. 1A into
COS-7 cells. The cell lysates were immunoprecipitated with anti-HA mAb, and subjected to an in vitro kinase assay using MBP as a
substrate, as described in Fig. 4C, HA-tagged ERK was co-transfected with RasV12, a constitutive active form of Ras (left panels).
HA-tagged JNK was co-transfected with Rac1V12 or Cdc42V12, constitutive active forms of Rac1 or Cdc42, respectively (right pan-
els). The cell lysates were immunoblotted with anti-active MAPK or anti-active JNK pAbs (upper panels). The expression levels of
ERK and JNK were checked by reprobing the same blot with anti-HA mAb (lower panels).
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S. cerevisiae), we characterized hSLK both structur-
ally and functionally.
In recent years, many SLKs have been cloned.
Based on their characteristics, they can be classi¢ed
into three families: PAK, PH-PAK and GCK fami-
lies [12]. In these families, only PH-PAK family
members have not yet been found in mammals. All
PAK and PH-PAK homologues possess conserved
serine/threonine kinase domains on the C-terminus
and GBDs on the N-terminus. Until now, four hu-
man PAKs (PAKs 1^4) have been identi¢ed [45^
47,50]. These PAKs were found to interact with
Cdc42 and Rac except for PAK4, which interacts
with Cdc42 but not with Rac. In addition, PAKs
1^3 activate JNK/SAPK and p38 pathways, and
PAK4 activates the JNK/SAPK pathway. hSLK
does not belong to PAK nor PH-PAK families for
the following reasons: (1) hSLK has a kinase domain
on its N-terminus and no GBD domain; (2) co-trans-
fection of hSLK with constitutive active forms of
GTPases (RasV12, RacV12 and Cdc42V12) does
not activate the hSLK kinase activity; and (3)
hSLK does not activate ERK, JNK/SAPK or p38
pathways.
Members of the GCK family have a common fea-
ture in the localization of the kinase domain on their
N-terminus. Thus, based on its domain structure,
hSLK belongs to the GCK family. The GCK family
can be subdivided into two groups based on the
structural and functional properties of its members
[30]. Group I GCKs are closely related to GCK itself
and include GCK, GCKR, GLK, HPK1 and NIK.
All members of this group interact with MEKK1, a
MAPKKK, and consequently activate the JNK/
SAPK pathway [19^21,27,51]. Structurally, group I
GCKs contain at least two PEST sequences and at
least two polyproline consensus binding sites for the
SH-3 domain. In addition, their CT regulatory re-
gions are conserved in two domains, a hydrophobic,
leucine-rich domain and a 140^150 amino acid
stretch called the CT region. hSLK contains four
PEST sequences on its CT regulatory domain; it,
however, contains neither a polyproline consensus-
binding site, a Leu-rich domain, nor the CT motif.
Furthermore, hSLK does not activate the JNK/
SAPK cascade. Based on these results, hSLK does
not appear to belong to the group I GCK family
The group II GCK family, including MST1^3,
SOK and LOK, does not activate any of the ERK,
JNK/SAPK or p38 MAPK pathways in mammals
except for MST1, which activates both JNK/SAPK
and p38 pathways. The kinases in this group are
more similar to S. cerevisiae SPS1, which is necessary
for sporulation, than the group I kinases. Although
these kinases contain a conserved kinase domain on
their N-terminus like the group I GCKs, the group II
GCKs possess neither a Leu-rich domain nor the CT
motif. Therefore, we concluded that hSLK is a newly
identi¢ed member of the group II GCKs.
Of all SLKs, hSLK is most similar to hLOK
(46.1% identical in full-length, 77.2% identical in ki-
nase domain). While hSLK is expressed ubiquitously,
the expression of LOK is restricted to lymphocytes.
hSLK and LOK share a common structure, the
coiled-coil structure, on their CT long regulatory do-
main. Coiled-coils are formed by two or three K-heli-
ces with repeats of seven residues [42]. Proteins with
the coiled-coil structure such as K-keratin are known
to oligomerize by means of this structure. hSLK
might also interact with itself or other coiled-coil
proteins, and the interaction might regulate the ki-
nase activity of hSLK.
Some members of the GCK family contain several
PEST sequences: GCK, three; GCKR, GLK, HPK1
and NIK, two; and MST1, LOK and SOK, only
one. In hSLK, four potential PEST sequences were
found between the N-terminal kinase domain and the
CT coiled-coil region. The PEST sequence is a motif
related to the rapid degradation of proteins [43,44].
Since hSLK is a constitutive active kinase in trans-
fected COS-7 cells, the kinase activity may be regu-
lated in part by a short half life due to the PEST
domain. Recently, another function of the PEST mo-
tif was clari¢ed in GCK. The PEST motifs on GCK
are necessary for interactions to occur with tumor
necrosis factor (TNF) receptor-associated factor 2
and MEKK1 [51]. By these interactions, GCK can
communicate a TNFK signal to nuclei via the JNK/
SAPK cascade. It is possible that hSLK associates
with up-stream or down-stream molecules using its
PEST sequences.
To determine which stimulations activate hSLK,
the COS-7 cells transfected with wild-type hSLK
were stimulated with growth factors, hyperosmolar-
ity, H2O2, anisomycin or UV, and the kinase activity
of hSLK was examined by an in vitro kinase assay
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(data not shown). However, autophosphorylation
levels were increased in none of the cells, and nor
was the kinase activity of hSLK. We have previously
reported that the autophosphorylation of guinea pig
SLK expressed in COS-7 cells is increased by the
stimulation of anisomycin in vivo [32]. The discrep-
ancy between in vivo and in vitro examinations
might be due to the high basal kinase activity of
hSLK. Since wild-type hSLK and it deletion mutants
already express quite high levels of kinase activity in
transfected COS-7 cells, this expression may have
obscured the di¡erence in the kinase activity. These
results seem to be a common feature of GCKs
The biological function of group II GCKs includ-
ing hSLK remains to be identi¢ed. Progress towards
clarifying the physiological function might be made
possible by identifying a molecule that binds to the
PEST motif and/or the coiled-coil structure. An ex-
amination of the importance of these motifs in hSLK
is now in progress.
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